Oppenheimer Initiates Coverage on Quince Therapeutics (NASDAQ:QNCX)

Oppenheimer started coverage on shares of Quince Therapeutics (NASDAQ:QNCX) in a report released on Monday, Marketbeat.com reports. The brokerage issued an outperform rating and a $10.00 price target on the stock.

Several other analysts have also recently issued reports on QNCX. Brookline Capital Management initiated coverage on Quince Therapeutics in a research report on Wednesday, December 18th. They set a “buy” rating and a $9.00 target price on the stock. D. Boral Capital reiterated a “buy” rating and issued a $12.00 target price on shares of Quince Therapeutics in a research note on Wednesday, February 5th. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $9.60.

Quince Therapeutics Trading Up 1.4 %

NASDAQ:QNCX opened at $1.40 on Monday. The firm has a 50-day simple moving average of $1.49 and a 200-day simple moving average of $1.44. Quince Therapeutics has a one year low of $0.51 and a one year high of $2.45. The firm has a market cap of $61.60 million, a P/E ratio of -1.13 and a beta of 0.71. The company has a debt-to-equity ratio of 0.33, a quick ratio of 9.53 and a current ratio of 9.53.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in QNCX. Anfield Capital Management LLC acquired a new stake in Quince Therapeutics in the fourth quarter worth about $50,000. Virtu Financial LLC acquired a new stake in Quince Therapeutics in the 4th quarter worth approximately $55,000. Two Sigma Investments LP acquired a new position in Quince Therapeutics during the 4th quarter valued at approximately $57,000. Northern Trust Corp increased its stake in Quince Therapeutics by 48.5% during the 4th quarter. Northern Trust Corp now owns 50,524 shares of the company’s stock valued at $94,000 after purchasing an additional 16,501 shares in the last quarter. Finally, Scharf Investments LLC purchased a new position in shares of Quince Therapeutics in the fourth quarter worth $170,000. 30.75% of the stock is currently owned by hedge funds and other institutional investors.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.